Brahmer et al. reported that blocking PD-L1 by using an anti-PD-L1 mAb results in both durable tumor regression (objective response rate, 6% to 17%) and prolonged (≧24 weeks) disease stabilization in patients [15]. This evidence concerns the gene CD274 and neoplasm.